Adaptive Biotechnologies Corporation - Common Stock (ADPT)

Small caps took another step down this past week as geopolitical events dampened sentiment.

The company expects sales to grow 12% to 13% annually in the long term.

Cathie Wood-led Ark Invest sold 140,518 shares of Palantir and bought shares of Tempus AI Inc. The total value of the trades is about $9.1 million.

Ark Invest, led by Cathie Wood, made significant trades in 5 companies on Friday: RXRX, ILMN, NTLA, NET, and ADPT.

The healthcare sector is lagging over the past year and recent quarter with the XLV flat for 2024 and down over 4% for the recent quarter.

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.

The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings.

It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever.

With technological developments pushing the boundaries of healthcare, these are the precision medicine stocks to consider.

Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a broader market where technology rules.

While small-cap stocks to buy present a higher-risk profile, these ideas may also pack considerable punch for their size.

The popular growth investor keeps adding to some of her favorite falling stocks.